SCHOTT Pharma AG & Co. KGaA/€1SXP

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About SCHOTT Pharma AG & Co. KGaA

SCHOTT Pharma AG & Co. KGaA specializes in the design and manufacture of drug containment and delivery solutions for injectable medications, including prefillable glass and polymer syringes, cartridges, vials, and ampoules. Established as a standalone entity in August 2022 following its separation from SCHOTT AG, the company is headquartered in Mainz, Germany, and operates 16 manufacturing sites across Europe, North and South America, and Asia. With a portfolio of over 1,000 patents and a dedicated R&D center in Switzerland, SCHOTT Pharma focuses on developing innovative solutions to meet the evolving needs of the pharmaceutical industry. The company serves over 1,800 customers, including the top 30 pharmaceutical manufacturers for injectable drugs, and reported revenues of €821 million in the fiscal year 2022. SCHOTT Pharma is committed to sustainable development, aiming to achieve climate neutrality by 2030.

Ticker

€1SXP
Sector
Health

Primary listing

XETRA

Employees

4,775
Headquarters
Mainz, Germany
Website
www.schott-pharma.com

1SXP Metrics

BasicAdvanced
€3.2B
21.94
€0.97
-
€0.16
0.75%

Bulls say / Bears say

Second-quarter revenues reached €252 million, up 10% year-over-year at constant currencies, surpassing consensus estimates by 5%, reflecting solid demand for core products.
Q2 EBITDA margin grew to 28.6%, an increase of 9.7 percentage points year-over-year driven by higher-margin solutions, exceeding pre-quarter forecasts by 3 percentage points.
High-value solutions accounted for 56% of Q2 sales, demonstrating a successful portfolio shift that boosts profitability and strengthens business resilience.
The EBITDA margin for the DDS segment decreased by 4 percentage points year-over-year to 34.4%, highlighting ongoing difficulties in the glass syringe business despite broader growth.
Profitability in Q2 was negatively affected by ramp-up expenses and temporary underutilization at facilities in Hungary and Serbia, pointing to short-term pressure on margins.
Management reduced its full-year CapEx guidance to €140-160 million and left margin targets unchanged, signaling a cautious outlook amid macroeconomic uncertainty and possible demand swings.
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €1SXP

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs